Boehringer Ingelheim Fremont, Inc.
6701 Kaiser Drive
About Boehringer Ingelheim Fremont, Inc.
Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.
One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.
A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.
Biopharmaceuticals - Competence and Experience for Medicines of the Future Over 35 years ago, Boehringer Ingelheim started developing and producing biopharmaceuticals as one of the first companies worldwide. Biopharmaceuticals are produced by using either mammalian cell cultures or microorganisms such as bacteria or yeast.
1004 articles about Boehringer Ingelheim Fremont, Inc.
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy
CDR-Life Inc. announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy.
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
Boehringer Ingelheim, a global leader in animal health, has received marketing authorization from the European Commission for SENVELGO®, marking a significant step for the treatment of feline diabetes in Europe.
Novel AI-Driven Model Validated to Predict Risk of Chronic Kidney Disease Progression in Large U.S. Study
Boehringer Ingelheim and Carelon Research have conducted a validation study of the Klinrisk model, a machine-learning tool developed to predict the risk of chronic kidney disease progression at all stages of the disease.
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics
Burning Rock Biotech Limited is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement in the field of oncology companion diagnostics.
Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support
In a unique partnership, Boehringer Ingelheim Ltd., St. Joseph's Healthcare Hamilton, and McMaster University have come together to transform the way patients are supported at the onset of a diagnosis related to interstitial lung disease.This collaboration marks a significant leap forward in patient-centric care, driven by empathy and understanding.
Remedium Bio is excited to announce that the company has been selected as a finalist for the in-person pitch competition at the upcoming Boehringer Ingelheim External Innovation Day.
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Boehringer Ingelheim and Zealand Pharma A/S announced the initiation of three Phase III trials investigating survodutide for people living with overweight or obesity.
The Scleroderma Research Foundation, the nation's largest non-profit funder of scleroderma research, announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will contribute an experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF.
Adalimumab-adbm, Boehringer Ingelheim's Interchangeable biosimilar to Humira®, now available at low wholesale acquisition cost
Boehringer Ingelheim announced that Adalimumab-adbm injection, the company's interchangeable* biosimilar to Humira®, is now available at a low wholesale acquisition cost.
Oxford BioTherapeutics to Participate in Panel Discussion at Boehringer Ingelheim’s Upcoming Transforming Science Day: Europe
Oxford BioTherapeutics announces that its Chief Executive Officer, Christian Rohlff, will participate in the panel discussion titled “It takes a village: A holistic approach to external innovation” at Boehringer Ingelheim’s upcoming Transforming Science Day: Europe.
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets from the Science Based Targets initiative.
Boehringer Ingelheim receives FDA approval for SENVELGO® (velagliflozin oral solution): the first oral liquid medication for diabetes in cats
Boehringer Ingelheim announced that SENVELGO®, a revolutionary new treatment for cats with diabetes, has been approved by the U.S. Food and Drug Administration.
CDR-Life Announces Second Milestone Achievement with Boehringer Ingelheim in Developing Antibody Fragment-based Therapeutics for Geographic Atrophy
CDR-Life Inc. announced a milestone payment triggered by the achievement of a development milestone with a partnered antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy.
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health expanding across its key therapy areas.
Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Boehringer Ingelheim announced that the U.S. Food and Drug Administration has approved the newest innovation from the trusted NexGard® Brand of Products — NexGard® PLUS — a monthly beef-flavored soft chew that protects dogs from fleas, ticks, heartworm disease, roundworms and hookworms.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Boehringer Ingelheim announced that Cyltezo®, a U.S. Food and Drug Administration -approved Interchangeable biosimilar to Humira®, is now commercially available in the U.S. Cyltezo was initially approved as a biosimilar in 2017 for use in multiple chronic inflammatory diseases.
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
Boehringer Ingelheim and Zealand Pharma A/S announced additional data demonstrating superior efficacy with survodutide versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment.1 The findings were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S.
American Academy of Dermatology launches innovative project to improve outcomes for patients with life-threatening pustular psoriasis
The American Academy of Dermatology is launching an innovative breakthrough project to develop educational resources to improve the evaluation, diagnosis, and treatment of patients suffering from generalized pustular psoriasis, a rare form of psoriasis that causes widespread, pus-filled blisters, called pustules.
Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology
Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate -based therapies, announced that it has extended its second multi-year collaboration with Boehringer Ingelheim for an additional two years.
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
Boehringer Ingelheim and Zealand Pharma A/S announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose.